文献速递瓣膜外科

低剂量华法林联合新型机械主动脉瓣:5年随访中期注册研究结果

Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-04-28

这项前瞻性观察性注册研究评估On-X机械主动脉瓣植入后以国际标准化比值1.8(范围1.5-2.0)为目标的华法林联合每日阿司匹林75-100 mg的安全性,在美国、英国和加拿大23个中心纳入510例成人患者,中期分析纳入229例计划于2023年8月16日前完成5年随访者。主要复合终点(大出血、瓣膜血栓和血栓栓塞)线性发生率1.83%/患者年,对照为标准剂量华法林(INR 2.0-3.0)联合阿司匹林81 mg/d的前瞻性随机On-X抗凝试验对照组5.39%(95%CI 4.12%-6.93%)。中期结果支持On-X主动脉机械瓣联合INR 1.8目标及低剂量阿司匹林在植入后5年内的持续安全性,无论是否家庭监测。

要点

  • On-X主动脉瓣植入后INR 1.8(1.5-2.0)联合阿司匹林75-100 mg/d,主要复合终点1.83%/患者年 vs 对照组5.39%。
  • 大出血和总出血分别较对照组降低87%和71%,血栓栓塞事件未见增加。
  • 诊室监测与家庭监测患者、血栓栓塞高危患者中结果一致。

核心结论

  • 中期结果支持On-X主动脉机械瓣以INR 1.8为目标联合低剂量阿司匹林在植入后5年内的持续安全性,无论是否家庭监测。

研究设计与样本

  • 前瞻性观察性临床注册研究,评估成人On-X机械主动脉瓣植入后接受低剂量华法林(目标INR 1.8,范围1.5-2.0)联合每日阿司匹林75-100 mg治疗5年期间的不良事件率。
  • 2015年11月至2022年1月在美国、英国和加拿大23个中心共招募510例患者,本次中期分析纳入229例计划于2023年8月16日前完成5年随访者。
  • 对照为标准剂量华法林(INR 2.0-3.0)联合每日阿司匹林81 mg的前瞻性随机On-X抗凝试验对照组患者。

主要发现

  • 主要复合终点(大出血、瓣膜血栓和血栓栓塞)线性发生率为1.83%/患者年,对照组为5.39%(95%CI 4.12%-6.93%)。
  • 大出血和总出血分别较对照组降低87%和71%,血栓栓塞事件未见增加。
  • 诊室监测与家庭监测患者以及血栓栓塞高危患者中结果一致。

关键数值与推荐

  • 低剂量华法林目标INR 1.8(范围1.5-2.0)联合阿司匹林75-100 mg/d。
  • 对照标准剂量华法林INR 2.0-3.0联合阿司匹林81 mg/d。
  • 主要复合终点线性发生率1.83%/患者年 vs 对照组5.39%(95%CI 4.12%-6.93%)。

临床怎么用

  • 中期结果支持On-X主动脉机械瓣以INR 1.8为目标联合低剂量阿司匹林在植入后5年内的持续安全性,无论是否家庭监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether warfarin targeted at an international normalized ratio of 1.8 (range, 1.5-2.0) after On-X mechanical aortic valve implant is safe for all patients. METHODS: This prospective, observational clinical registry assessed adverse event rates in adult patients receiving low-dose warfarin (target international normalized ratio, 1.8; range, 1.5-2.0) plus daily aspirin (75-100 mg) during a 5-year period after On-X aortic valve implant. The primary end point is the combined rate of major bleeding, valve thrombosis, and thromboembolism overall and in 4 subgroups. The comparator is the Prospective Randomized On-X Anticoagulation Trial control group patients on standard-dose warfarin (international normalized ratio, 2.0-3.0) plus aspirin 81 milligrams daily. RESULTS: A total of 510 patients were recruited at 23 centers in the United States, United Kingdom, and Canada between November 2015 and January 2022. This interim analysis includes 229 patients scheduled to complete 5-year follow-up by August 16, 2023. The linearized occurrence rate (in percent per patient-year) of the primary composite end point of major bleeding, valve thrombosis, and thromboembolism is 1.83% compared with 5.39% (95% confidence interval, 4.12%-6.93%) in the comparator group. Results are consistent in clinic-monitored and home-monitored patients and in those at high risk for thromboembolism. Major bleeding and total bleeding were reduced by 87% and 71%, respectively, versus the comparator group, without an increase in thromboembolic events. CONCLUSIONS: Interim results support the continued safety of the On-X aortic mechanical valve with a target international normalized ratio of 1.8 plus low-dose aspirin through 5 years after implant, with or without home monitoring.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Gerdisch MW, Hagberg RC, Perchinsky MJ, et al. Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up. J Thorac Cardiovasc Surg. 2024. PMID: 38688451. doi:10.1016/j.jtcvs.2024.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。